Ashvattha Therapeutics

formerly AVTTX

Developing a New Class of Intracellular Targeted Therapeutics

San Francisco, United States · Founded 2016 · $188.0M raised

Employees
11–50
Founded
2016
Business Model
B2B
Website
avttx.com
Total Funding
$188.0M
Last Round
$50.0M Extension RoundJan 2025
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company founded by Johns Hopkins scientists that develops hydroxyl dendrimer-based nanomedicines targeting activated microglia and macrophages in diseased tissue. Its lead program, migaldendranib (MGB), is in Phase 1/2 clinical trials for retinal and inflammatory conditions, with the technology enabling precise intracellular drug delivery without affecting healthy cells.

Summary

Ashvattha Therapeutics is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $188.0M in total across 3 rounds, most recently a $50.0M Extension Round in Jan 2025. Investors include Natural Capital, Tribe Capital and Kennet Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundJan 2025
$50.0M

Sign up to see all 3 events

Funding: Series B through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ashvattha Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/ashvattha-therapeutics"><img src="https://indexed.vc/api/badge/company/ashvattha-therapeutics" alt="Ashvattha Therapeutics on Indexed.vc" width="260" height="76" /></a>